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ABSTARCT 
 
Duchenne Muscular Dystrophy (DMD), characterized by the lack of dystrophin, results 
from a mutation in the Xp21 gene which encodes for the protein dystrophin that links the 
extracellular matrix to the actin cytoskeleton in skeletal, cardiac and smooth muscle. Slow colonic 
transit and chronic constipation are common in DMD patients due to the weakening of the 
abdominal wall muscles and gut smooth muscle. However, the cause of this hypocontractility in 
DMD patients and the expression of contractile proteins in smooth muscle are unknown. 
Expression of contractile proteins is regulated by the signaling pathways activated by excitatory 
(e.g., acetylcholine, ACh) and inhibitory transmitters (e.g., nitric oxide). Hydrogen sulfide (H2S) 
is well-known for its anti-oxidant effects; however, its utility to restore DMD-induced effects is 
unknown. Aim: To investigate the expression of contractile proteins and smooth muscle function 
in the colon of wild type mice and models of DMD (mdx and mdx/mTR mice) and the effect of 
H2S on these in mdx mice. Methods: Contraction of colonic segments was measured in the 
longitudinal orientation from 3-month old control and mdx mice, and 9-month old control and 
mdx/mTR mice, (mdx/mTR exhibit increased disease severity). The effect of SG1002, an orally 
active slow releasing H2S agent, was tested in mdx/mTR mice (40 mg/kg body weight in 
chow/every 3 days starting from 3 weeks to 9 months). Expression of contractile proteins was 
 8 
measured by qRT-PCR and western blot. Results: Expression of smoothelin, caldesmon, calponin 
and tropomyosin was decreased in colonic smooth muscle of mdx mice compared to control. This 
decrease was associated with a decrease in ACh-induced contraction in colonic segments (21 ± 3 
mN/100 mg tissue in control and 3 ± 1 mN/100 mg tissue in mdx mice). To identify the specific 
involvement of smooth muscle dysfunction in the decrease in contraction, colonic muscle cells 
were isolated and contraction in response to ACh was measured by scanning micrometry and 
expressed as the percent decrease in cell length from control cell length.  ACh-induced contraction 
was also inhibited in muscle cells isolated from mdx mice compared to control (43±5% in control 
and 27±3% in mdx mice). ACh-induced contraction was decreased in colonic segments from 
mdx/mTR mice (12 ± 2 mN/100 mg tissue in control versus 4 ± 1 mN/100 mg tissue in mdx/mTR) 
and the decrease was partly reversed by SG1002 treatment (9 ± 1 mN/100 mg tissue). mRNA 
expression of thin filament associated proteins was also decreased in colonic smooth muscle from 
mdx/mTR mice and the decrease was reversed by SG1002. These results suggest that H2S restores 
contractile protein mRNA expression and contraction in mdx/mTR mice. Conclusion: The data 
indicate that the lack of dystrophin in mdx mice adversely affects colonic smooth muscle 
contractility through the down regulation of contractile protein mRNA expression. Treatment of 
mdx/mTR mice with H2S restores contractile phenotype. Thus, H2S treatment would be an area of 
study in therapeutic control of DMD-induced gastrointestinal motility disorders.  
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Chapter 1: INTRODUCTION 
  
1.1: Background Duchenne Muscular Dystrophy 
Duchenne Muscular Dystrophy (DMD) is a rapidly progressive neuromuscular and 
X-linked disorder that affects 15.9 to 19.5 per 100,000 live births, characterized by muscle 
weakness with eventual disability (Yucel et al., 2018) (Ryder et al.2017).  It is caused by 
mutations in the gene located at Xp21, which encodes for the protein dystrophin. 
Continuous muscular damage and muscle fiber degeneration is evident in patients suffering 
from DMD, causing muscular weakness that is associated with motor delays, loss of 
ambulation, respiratory impairment and cardiomyopathy (Birnkrant et al., 2018). Effects 
of this genetic disorder are apparent in individuals early on from ages 1-3 through 
symptoms such as delayed walking, frequent falls, and difficulty climbing stairs due to the 
effects that a lack of dystrophin has on the muscular system (Ryder et al.2017).  In terms 
of the gastro-intestinal system, chronic constipation is highly prevalent and an ongoing 
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source of discomfort and distress in DMD patients- this is specifically due to the struggles 
of GI motility caused by the manifestation of the DMD phenotype on gastrointestinal 
smooth muscle (Brumbaugh et al., 2018) (Lo Cascio et al., 2016). Chronic constipation in 
DMD patients requires the regular use of laxatives and enemas, promoting life-threatening 
metabolic acidosis through the loss of bicarbonate, furthering the complications associated 
with the consequences of DMD (Lo Cascio et al., 2014). Most people with DMD die from 
cardiac failure before or during their 30s as the cardiomyopathy that develops in DMD 
causes the heart chambers of individual to enlarge and the walls to thin out, ultimately 
leading to the development of heart failure (Ryder et al., 2017). Although death is 
inevitable, the gastrointestinal effects of DMD result in a very poor quality of life for 
patients suffering from the disease. 
1.2: Dystrophin Introduction- Background, Function, and Pathogenesis 
DMD is caused by mutations in the gene that encodes for the 427-kD cytoskeleton 
protein dystrophin (Nowak & Davies 2004). The dystrophin gene is the largest in the 
human genome, consisting of 2.6 million base pairs of DNA and 79 exons. The full-length 
dytrophin isoform, dp427, is generated from three distinct, tissue specific promoters: the 
(M) muscle type promoter that drives expression of dystrophin in all three muscle groups, 
the brain-type (B) promoter that drives dytrophin expression in cortical and cerebellar 
neurons and the heart, and the purkinje type (P) promoter that drives cerebellar dystophin 
expression (Petkova et al., 2016). Around 60% of the mutations of dystrophin are due to 
large insertions or deletions that lead to further downstream frameshift errors (Nowak & 
Davies 2004). 
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Structurally, the dystrophin protein plays a critical role in muscles in linking the 
intracellular actin cytoskeleton of a myocyte to the extracellular matrix via the dystrophin 
associated protein complex (DAPC), protecting the sarcolemma from contractile stress 
(Blake et al., 2002) (Petkova et al., 2016) (Petrof 2002). Dystrophin contains four main 
functional domains: an amino (N) terminus that connects to the intracellular F-actin 
cytoskeleton, the central rod domain that contains spectrin-like repeats, the cysteine rich 
domain, and the carboxyl terminus that binds the DAPC, providing the link between the 
intracellular cytoskeleton and the ECM (Guiraud et al., 2015) (Renzhi et al., 2011) (Wang 
et al., 2016). The spectrin-like repeats of dystrophin’s rod like domain predict that 
dystrophin may function as a shock absorber, resisting multiple rounds of muscle 
contraction and relaxation (Guiraud et al., 2015). Furthermore, dystrophin itself assembles 
several transmembrane proteins and cytoplasmic proteins into the DPAC, which is divided 
into: the dystroglycan complex, sarcoglycan complex, and cytoplasmic and ECM 
components. Ultimately, the DAPC connects the cytoskeleton with the ECM, leading to 
the mechanical stability of the sarcolemma and protection against contraction-induced 
muscle damage (Petkova et al., 2016). The vast majority of patients with DMD completely 
lack dystrophin; however, even with reduction in the amount or alteration in the size of the 
dystrophin gene leads to a less severe type of muscular dystrophy of Becker’s Muscular 
Dystrophy, suggesting the crucial impact dystrophin has on the muscular system (Nowak 
& Davies 2004). 
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Figure 1. Diagram of Dystrophin (Kamdar 2016 JACC). Schematic diagram of DGC 
(dystroglycan complex). DGC is seen to span the sarcolemmal membrane and link the cytoplasmic 
actin cytoskeleton to the ECM via dystrophin. The DGC includes sarcoglycans, β-dystroglycan, 
and extracellular α-dystroglycan. Cytoplasmic components include dystrophin which binds to 
dystrobrevin, syntrophin, and nitric oxide synthase. 
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1.3: Dystrophin- Skeletal Muscle 
Skeletal muscles are dynamic tissues that undergo stress from each contraction. The 
connection between the cytoskeleton of the muscle cell and the ECM is imperative for 
maintaining cellular integrity and function during each cycle of contraction and stress 
(Guiraud et al., 2015) (Renzhi et al., 2011) (Wang et al., 2016). In completely regular, non-
affected skeletal muscles, the susceptibility for mechanical damage is ongoing; however, 
homeostasis is maintained through injury repair by muscle stem cells and satellite cells.  In 
DMD, DAPC, which is responsible for the physical connection of the sarcolemmal 
cytoskeleton with the ECM, loses its ‘structural linkage’ due to the loss of dystrophin, 
making the sarcolemma prone to further damage by mechanical stress and leaving the 
repair processes incapable of maintaining homeostasis (Beyers et al., 1993). Now during 
contraction, there is sarcolemmal damage, an increase in membrane permeability to Ca++ 
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and small ions, leading to cell death and dysfunction. This imbalance between skeletal 
muscle degeneration to regeneration initiates the process of fibrosis via inflammatory 
processes, which is a hallmark of DMD (Guiraud et al., 2015) (Han et al., 2011). 
Histologically, normal skeletal muscles consist of muscle fibers that are evenly spaced, 
angular, and uniform in size; on the contrary, DMD muscle biopsies show necrotic and 
degenerative muscle fibers, with the lost muscle myofibers being replaced by connective 
tissue and fat (Blake et al., 2002) (Guiraud et al., 2015).  
 
1.4: Dystrophin- Cardiac Muscle 
95% of patients with DMD develop cardiomyopathies by the age of 20, and cardiac 
failure is one of the major sources of mortality in DMD patients, with respiratory failure 
being the other (Birnkrant et al., 2018) (Mourkioti et al., 2013) (Kaprielian and Severs 
2000). Cardiac muscles of DMD patients either completely lack dystrophin or have a 
truncated version of the protein. It is understood that dystrophin plays a role in linking the 
cytoskeleton to the ECM via DAPC (Mourkioti et al., 2013). It is the cytoskeleton that 
allows cardiomyocytes to a maintain their characteristic shape and structure despite the 
contraction-induced damage imposed on the cardiac muscle cells from the cyclic 
contractions of the heart (Mourkioti et al., 2013) (Kaprielian and Severs 2000) (Kuo and 
Ehrlich 2015). 
Compared to skeletal muscles, dystrophin in cardiomyocytes is not only distributed 
along the sarcolemma, but also the transverse tubules, where it is not seen in the skeletal 
muscles (Kaprielian and Severs 2000) (Kaprielian et al., 2000) (Byers et al., 1991). 
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Dystrophin is also absent from the membrane that overlays the adheren junctions of the 
intercalated discs (Byers et al., 1991) (Kaprielian and Severs 2000).  
Dystrophin’s structural role in providing membrane stability and increased 
mechanical strength of the myocyte membrane, it is well understood that in 
cardiomyocytes, like in skeletal muscles, it plays an important role in regulating the force 
of transmission in cardiomyocytes during the cyclic process of contraction in the heart 
(Kaprielian and Severs 2000) (Kaprielian et al., 2000) (Shirokova and Niggli 2013). 
Nevertheless, the distribution of dystrophin along the T-tubules suggests that dystrophin 
serves roles more than just contractile force as T-tubules are not directly affected by 
membrane distortion during cardiac contraction (Kaprielian and Severs 2000) (Kaprielian 
et al., 2000). 
 
1.5: Dystrophin- Smooth Muscle 
In smooth muscle cell membranes, dystrophin is not seen to be distributed uniformly 
across the SMC membrane, but more distantly and discontinuously (Beyers et al., 1991) 
(North et al., 1993). More specifically, dystrophin is seen to be dispersed in the caveolae-
rich domains of the smooth muscle cells (North et al., 1993).  
During the contraction of smooth muscles, the mechanical damage from muscle 
contraction falls upon the sarcolemma, where just as in skeletal and cardiac muscles, 
dystrophin provides the mechanical support to the SMC membrane via anchorage of the 
cytoskeleton to the ECM. Nonetheless, the distribution of dystrophin in caveolae-rich 
domains predicts interaction between these two structures, suggesting that dystrophin may 
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also act as a tension-sensing molecule that conveys information about sarcolemmal stress 
to the mechanosensitive Ca++ channels (Beyers et al., 1991). 
 A distinct feature found on contractile SMCs is the abundance of caveolae, 
exceeding 160,000 in number on a single SMC. Caveolae contribute to mechanisms that 
modulate contractile and proliferative activity with SMCs. They contain caveolins that are 
needed for scaffolding and signal-transduction (Halayko and Stelmack 2005).  Caveolin-1 
attaches to the intracellular tail of B-dystroglycan, the core transmembrane subunit of the 
dystrophin-glycoprotein complex (DGC/DPAC), which is linked to the intracellular actin 
via dystrophin and ECM laminin via a-dystrogycan. Caveolin-1 and dystrophin overlap at 
the membrane of contractile SMCs, where one of the key roles of dystrophin/DGC is to 
stabilize the plasma membrane to protect it against any damaging contraction-induced 
force. The close association of caveolins with DGC and cytoskeleton may also play a 
unique role in mediating and stabilizing the ordered compartmentalization of caveolae on 
the plasma membrane (North et al., 1993) (Beyers et al., 1991) (Halayko and Stelmack 
2005).  
 Disruption of DGC due to the loss of dystrophin leads to DMD; however, abnormal 
number, size, and shape of caveolae is also evident in DMD, suggesting that dystrophin is 
not only essential for providing protection against contractile stress, but also the 
organization of caveolae on the plasma membrane; an incompetent DGC from dystrophin 
loss leads to the compromise of caveolae compartmentalization (Halayko and Stelmack 
2005). 
1.6: Overview of Gastrointestinal Tract Structure and Function  
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The GI tract consists of a series of hollow organs that span from the oral 
cavity/mouth to the anus, with several accessory organs and glands that add secretions to 
these hollow organs. Each of these hollow organs are separated by sphincters, which allows 
these organs to have specialized functions. The mouth and the oropharynx are responsible 
for the mechanical digestion of dietary substances via mastication (chewing), lubrication 
of the food, initiation of carbohydrate and lipid digestion via salivary amylase and lingual 
lipase and propelling the food into the esophagus. The esophagus acts as conduit to the 
stomach, through which the bolus enters the stomach. The stomach temporary stores food 
and initiates mechanical digestion of dietary substances through churning, and chemically 
digests food through protease and hydrochloric acid (HCl) secretions. Once gastric 
contents are mixed with the hydrochloric acid and do not exceed a diameter of 2 mm, 
chyme is orderly transferred to the proximal small intestine (duodenum) through the 
pyloric sphincter, followed by peristaltic migration distally to the jejunum and then then 
the ileum. The small intestine is the ‘hotspot’ for nutrient absorption and continues the 
general digestive processes. Pancreatic enzymes/secretions and brush border enzymes of 
the small intestine complete digestion by breaking down dietary contents in the correct 
chemical form that allow for intestinal absorption. Contents of indigestion enter the colon, 
and travel through the cecum, ascending colon, transverse colon, descending colon, and 
sigmoidal colon, culminating in the rectum before it has amassed sufficiently to be excreted 
from the anus.   
Accessory organs and glands include the salivary glands, pancreas, and liver. The 
salivary glands secrete saliva, salivary amylase, and lingual lipase, all of which contribute 
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to the digestion of carbohydrates and lipids in the oral cavity. The pancreas secretes 
pancreatic enzymes such as chymotrypsin, amylase, and lipase for the digestion of proteins, 
carbohydrates, and lipids. In addition, it also secretes bicarbonate (HCO3-) to neutralize the 
incoming gastric acid from the stomach. Bile is produced in the liver and stored in the 
gallbladder for future delivery in the duodenum for lipid digestion/emulsification.  
 
1.7: Anatomy of Gastrointestinal Wall 
The alimentary canal is arranged into certain organizational layers that are common 
to all segments of the tract. Surrounding the luminal space of the GI tract is the mucosal 
layer that consists of an epithelial layer, an underlying layer of loose connective tissue 
called the lamina propria that contains enteric neurons, immune cells, and capillaries, and 
thin layer of smooth muscle known as the muscularis mucosae. Enclosing the mucosa is 
the submucosa, a layer of loose connective tissue that contains a larger vasculature than the 
lamina propria, along with the submucosal plexus (enteric neurons), and glands such as 
Brunner’s glands that secrete substances into the GI lumen. The submucosa is surrounded 
by the muscularis externa, that consists of an inner circular muscle layer and an outer 
longitudinal muscle layer. Both are responsible for peristalsis, which is characterized by a 
progressive wave of relaxation, followed by contraction. The serosa is an enveloping layer 
of connective tissue lined with mesothelium composed squamous epithelial cells, covering 
intraperitoneal organs. On the contrary, the adventitia is the outermost connective tissue 
layer that covers retroperitoneal organs anchored to the posterior abdominal wall.  
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1.8: Motility Functions of Colon (Large Intestine) 
Colonic contractions are regulated by myogenic, neurogenic, and hormonal factors. 
Parasympathetic control of the proximal two-thirds of the colon is mediated by the vagus 
nerve, whereas the parasympathetic control of the descending and rectosigmoid colon is 
mediated via pelvic nerves originating from the sacral spine.  
The proximal colon has two types of motor activity, non-propulsive segmentation 
and mass peristalsis. Non-propulsive segmentation is generated by slow-wave activity that 
produces circular-muscle contractions that churn and mix the ingesta, presenting them to 
the mucosa where absorption occurs and moving them in an caudad direction. 
Antiperistaltic contractions propagate toward the ileum, hampering the movement of the 
colonic contents through the colon, and allowing further absorption of water and 
electrolytes.  These segmental contractions are what give the large intestine its typical 
haustra appearance. Haustra are small pouches caused by sacculation, giving the colon its 
segmented look. The colonic contents during segmental mixing are retained in the proximal 
large intestine for long periods as fluid and electrolyte absorption continues- giving the 
large intestine its reservoir function. Mass peristalsis occurs when the colonic contents are 
propelled distally 20 cm or more, representing the major form of propulsive motility in the 
colon.  
The distal colon is primarily characterized by non-propulsive segmentation. It is in 
this distal colon that the final desiccation of colonic contents occurs and where these 
contents are stored prior to an occasional mass peristalsis that propels them into the rectum. 
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The rectum itself is kept nearly empty by non-propulsive segmentation until it is filled by 
mass peristalsis of the distal end of the colon. Filling of the rectum triggers a series of 
reflexes in the internal and external sphincters that ultimately lead to defecation.  
 
1.9: Smooth Muscle Structure with Contractile Protein Emphasis 
Smooth muscles are distributed in the walls of various organs and systems, ranging 
from blood vessels, stomach, intestines, bladder, airways, uterus, and the penile and clitoral 
cavernosal sinuses (Webb 2003). Smooth muscle cells lack the striated banding pattern 
found in cardiac and skeletal muscles and receive neural innervation from the autonomic 
nervous system. The contractile state of the smooth muscle is controlled by hormones, 
autocrine/paracrine agents, and other local chemical signals. Changes in load or length also 
develop the tonic and phasic contractions of the SMC’s. Regardless of what stimulus 
regulates the contractile state in SMC’s, the cross-bridge cycling between actin and myosin 
is what ultimately develops force, with Ca++ ions initiating contractions (Gunst and Tang 
2000). 
The contractile apparatus of smooth muscles is very similar to skeletal but is not as 
highly organized into discrete sarcomeres as in the striated muscles. Thick myosin 
filaments and thin actin filaments are the primary constituents of the smooth muscle 
contractile apparatus, colocated in the contractile domain of the cell (Horowitz et al., 1996) 
(Morgan and Gangopadhyay 2001) (Wang et al., 2012).  
Thin filaments are 6-8 nm in diameter and contain actin, which exists as F-actin in 
vivo, as their main protein constituent. Furthermore, the cellular content of actin in smooth 
 21 
muscle is ~ twice that of striated muscles. It is well understood that actin-myosin 
interaction initiates contraction in all three muscle groups; however, there are thin-filament 
regulatory proteins in smooth muscle that associate with actin and modulate cross-bride 
function but are understood at a lesser extent (Babu et al., 2000). 
Thick filaments are bipolar assemblies composed of multiple myosin molecules. 
Each myosin aggregate is composed of two intertwined heavy chains (SM-MHC), a pair 
of 17-kDa non-phosphorylatable alkali light chains (ELC), and a pair of regulatory 20-kDa 
light chain (MLC20). The myosin heavy chain dimers form globular amino terminal heads 
and coiled-coil tails at their carboxy terminus. The myosin head has an intrinsic actin-
activated Mg2+ ATPase activity, through which myosin is able to transform the chemical 
energy stored in ATP to mechanical work associated with smooth muscle contraction. 
Mucle contraction is driven by the cyclical interaction between the myosin thick filament 
and actin thin filaments coupled with ATP hydrolysis (Farah and Reinach 1995). A cross 
bridge is formed between the actin and myosin, that produces force and movement as it 
‘tilts’ into subsequent bound states until finally detaching (Babu et al., 2000) (Viegal et al., 
2003).  
 
 
1.10: Excitation Contraction Coupling and Thin Filament-Associated Proteins 
In all three muscle types, an increase in [Ca++]i triggers contraction via the removal 
of cross-bridge cycling inhibition (Farah and Reinach 1995) (Holda et al., 1998) (Horowitz 
et al., 1996) (Merlini et al, 2003). An increase in intracellular Ca++ concentrations in the 
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smooth muscle initiates certain processes that ultimately increase the ATPase activity of 
myosin. Binding of four Ca++ ions to calmodulin forms the Ca++-Calmodulin complex that 
activates myosin light chain kinase (MLCK), responsible for phosphorylating the 
regulatory 20-kDa light chain. The principal function of calmodulin in smooth muscle is 
to activate cross-bridge cycling and development of force in response to the transient 
increase in intracellular calcium concentration. Rather than troponin C (as in striated 
muscles), calmodulin is the calcium binding protein responsible for contraction 
transduction (Farah and Reinach 1995) (Holda et al., 1998) (Horowitz et al., 1996) (Merlini 
et al, 2003). This phosphorylation of Ser19 on the 20-kDa regulatory light chain of myosin 
is fundamental for the actin-activated myosin ATPase and interaction between actin and 
myosin which initiate smooth muscle contraction (Farah and Reinach 1995) (Holda et al., 
1998) (Horowitz et al., 1996) (Kuo and Ehrlich 2015) (Walsh 1994).  
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Figure 2. Smooth Muscle Contraction. This figure shows a general summary of the process of 
smooth muscle contraction. The initial pathway is Ca++ and calmodulin (CaM) dependent, where 
the Ca++/CaM complex activate the myosin light chain kinase (MLCK), triggering contraction via 
myosin light chain (MLC20) phosphorylation. This represents the initial contraction. The sustained 
pathway is Ca++/CaM independent and requires the inhibitions of myosin light chain phosphatase 
(MLCP) to keep the MLC20 phosphorylated and the contraction sustained.  
GPCR: G-Protein Coupled Receptor; PLC-β1: Phospholipase C β-1 ; IP3: Inositol 1,4,5-
triphosphate; SR: Sarcoplasmic Reticulum; Ca++: Calcium; CaM: Calmodulin; MLCK: Myosin 
Light Chain Kinase; MLC20-P: 20 kD Myosin Light Chain; MLCP: Myosin Light Chain 
Phosphatase; RhoA: Ras Homolog gene family, member A; ROCK: Rho associated, coiled-coil-
containing protein kinase 1; CP17: C-potentiated Inhibitor 17; PKC: Protein Kinase C;  
 
 
 
 
 
This mechanism pertains specifically to thick filaments, and it is apparent that 
smooth muscle cross-bridges are regulated by the phosphorylation of MLC20; however, 
additional regulation of smooth muscle contraction through thin-filament associated 
proteins is indicated. Thin-filament regulation is one of several mechanisms invoked to 
explain the well-known capacity of smooth muscles to maintain tone at low MLC20 
phosphorylation. These thin-filament associated proteins include: tropomyosin, calponin, 
caldesmon, and smoothelin (Horowitz et al., 1996) (Morgan and Gangopadhyay 2001).  
Tropomyosin. Individual tropomyosin molecules consist of two identical alpha 
helices that coil around each other and sit near the two grooves that are formed by the two 
helical actin strands. The head to tail contact between adjacent tropomyosin proteins results 
in a continuous filament that spans around seven actin monomers (Farah and Reinach 1995) 
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(Holda et al., 1998) (Horowitz et al., 1996) (Merlini et al, 2003). The role of tropomyosin 
is to interfere with the binding of myosin to actin. In skeletal muscles, through its 
interaction with the troponin complex, tropomyosin acts as a Ca++ switch turning myosin 
ATPase activity on and off (Farah and Reinach 1995) (Holda et al., 1998) (Horowitz et al., 
1996) (Merlini et al, 2003). In smooth muscles, tropomyosin’s role is less clear due to the 
lack of troponin; however, it is suggested that tropomyosin inhibits acto-myosin ATPase 
activity in smooth muscle as well, through its interaction with caldesmon17,27,33,62.  
Caldesmon. Caldesmon is an actin, tropomyosin, myosin, and calmodulin binding 
protein. Like the other thin-filament associated proteins, caldesmon also tonically inhibits 
the ATPase activity of myosin in smooth muscle. It inhibits actin-activated Mg2+-ATPase 
of smooth muscle myosin by reducing the affinity between actin and myosin. This 
inhibition is a result of competition between caldesmon and the myosin head for a binding 
site on actin as both can displace one another from the actin thin filament. Structurally, the 
carboxy-terminal domains of caldesmon are responsible for actin binding and inhibition of 
myosin ATPase activity in vitro. The amino-terminal domains bind to myosin and tethers 
myosin to actin in conjunction with the C-terminal actin binding domains. There are also 
two high-affinity tropomyosin binding sites on the C-terminal domain of caldesmon and 
between resides 230 and 419, indicating the function caldesmon plays in tropomyosin-
mediated inhibition of acto-myosin ATPase activity. Furthermore, it is observed that the 
presence of tropomyosin increases caldesmon-actin binding affinity (Farah and Reinach 
1995) (Holda et al., 1998) (Horowitz et al., 1996) (Merlini et al, 2003) (Morgan and 
Gangopadhyay 2001). 
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Calponin. Calponin is another thin-filament associated protein that like caldesmon, 
tonically inhibits the interaction between myosin and actin. Its function of binding to F-
actin and inhibition of ATPase activity are localized to its central domain. Calponin inhibits 
the ATPase activity of myosin heads cross-linked to actin resulting from a conformational 
change in actin induced by calponin binding and actin’s reduced capacity to activate 
myosin ATPase.  It contains three isoforms, h1, h2, and an acidic variant, with h1 being 
smooth muscle specific (Holda et al., 1998) (Horowitz et al., 1996) (Merlini et al, 2003) 
(Morgan and Gangopadhyay 2001).  
Smoothelin. Smoothelin’s are actin-binding proteins that are abundantly expressed 
in visceral smooth muscle as smoothelin-A, and expressed in vascular smooth muscle as 
smoothelin-B47. Both isoforms of smoothelin are found only in actively contracting smooth 
muscles. During pathological conditions associated with GI tract or vascular system, 
smoothelin-A and smoothelin-B expression is lower with adverse effects being apparent in 
the contractility of the two systems. Ultimately, it is understood that smoothelin is 
imperative for optimal contractility of smooth muscle, but the mechanism through which 
it accomplishes its function is not clear (Niessan et al., 2005).  
 
1.11: Excitation-Transcription Coupling  
Excitation-transcription coupling is a process that is highly dependent on [Ca++]i – 
specific stimuli and activates various transcription factors that elicit transcriptional 
responses depending on the conditions of the cell both extracellularly and intracellularly42. 
Smooth muscle cells of the vascular system require expression of a unique range of 
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contractile proteins/genes like SM-MHC, SM22alpa, calponin, smoothelin, etc (Misarkova 
et al., 2016) (Wamhoff et al., 2006).  
CREB (cAMP response element binding protein). CREB is highly expressed and 
active in quiescent smooth-muscle cells. It promotes smooth muscle gene expression and 
decreases proliferation through regulating the expression of cell cycle regulatory genes, 
genes encoding for growth factors, growth factor receptors, and cytokines. cAMP/PKA 
pathway, MAPK pathway, and more importantly the Ca++- Calmodulin complex, which 
activates MLCK and promotes MLC20 phosphorylation to induce contraction, also 
promotes the phosphorylation of CREB via CamK regulation (Wamhoff et al., 2006) 
(Marchand et al., 2012). 
NFAT and NFkB. NFAT transcription factors include 4 isoforms, NFAT1, 
NFAT2, NFAT3, and NFAT4. These factors are activated by calcineurin, a Ca++- 
Calmodulin-dependent phosphatase that is activated during EC/ET- coupling by myofibril 
Ca++ fluctuations. The dephosphorylation of NFAT by calcineurin allows for its 
translocation to the nucleus, where expression of SM-MHC and actin are increases, 
suggesting its role in regulating expression of different SMC marker genes (Marchand et 
al., 2012). 
Ca++/CArG element. Expression of the majority of SMC markers genes like actin, 
SM-MHC, SM22a, and h1 calponin have been shown to be dependent on at least one CArG 
element, located in the promoter-enhancer regions of these genes, and intracellular Ca++ 
concentration. During depolarization-induced calcium influx through the L-type voltage-
gated Ca++ channels, there’s an increase in the mRNA levels of actin, SM-MHC, and 
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SM22a. The L-type voltage-gated Ca++ channels activation was CArG dependent 
(Marchand et al., 2012).  
 
1.12: Muscular Dystrophy- Abnormal Gastrointestinal Motility  
Various clinical manifestations such as bloating, fullness, slow colonic transit, and 
chronic constipation have been reported in the gastrointestinal tract, often with life-
threatening complications. Despite postmortem evidence of significant gastro-intestinal 
smooth muscle degeneration in DMD, its mechanism, GI function, and treatment have not 
yet been systematically studied (Lo Cascio et al., 2016) (Mule et al., 2010). It has been 
speculated that reduced slow-wave activity, along with the reduced availability of intestinal 
NO (due to the lack of dystrophin) might be a possible mechanism for the reduced intestinal 
motility and transit time (Lo Cascio et al., 2016) (Mule et al., 2010). Furthermore, this lack 
of dystrophin causes the linkage between the cytoskeleton and extracellular matrix to 
break, making muscles more susceptible to contraction-induced damage. This damage is 
associated with plasma membrane tears and ruptures, causing Ca++ influx and intracellular 
overload of Ca++. There are morphological signs of significant reduction in the thickness 
of the muscular layer, mucosal degeneration and damage to the internal membrane of 
mitochondria in the large intestine of DMD mice. Nonetheless, the cause of this damage 
and reduced contractility is not fully understood (Alves et al., 2014) (Ryder et al., 2014) 
(Sarna et al., 2010). 
 
1.13: Oxidative Stress 
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Oxidative stress and inflammation are proposed pathogenic mechanisms that can 
explain the dystrophic pathophysiology. Smooth muscles lacking functional dystrophin 
have an increased susceptibility to sarcolemmal damage after muscle contraction, leading 
to necrosis and oxidative stress, where this stress seems to exacerbate the pathology of 
DMD. The precise understanding of why this dystrophin deficiency causes ROS 
production is not clear; however, it likely correlated with the excessive amounts of 
intracellular Ca++ coupled with inflammation (Chahbouni et al., 2010).  
Elevated cytosolic Ca++ levels lead to an increase in mitochondrial Ca++, which is 
an effector of ATP synthesis. An increase in ATP synthesis causes an increase in the ROS 
production by the mitochondria through higher O2 consumption and enhanced e- flow 
through the electron transport chain (Terril et al., 2013).  Membrane damage, due to the 
contraction-induced damage in dystrophin deficient smooth muscles, results in the 
degranulation of mast cells and release of intracellular contents, activating the immune 
system. Immune cells like neutrophils and macrophages generate ROS in order to promote 
phagocytosis. NFkB immunoreactivity has also been detected in the plasma, macrophages 
and necrotic and non-necrotic fibers in the muscle of DMD patients. The NFkB 
transcription factor plays a role in the expression of TNFa and IL-1B, which in turn 
stimulate further production of ROS (Chahbouni et al., 2010) (Singh and Lin 2015). 
 
1.14: Hydrogen Sulfide (H2S) – Physiological Effects 
Smooth muscle relaxation. Hydrogen Sulfide is well-known as a poisoning and 
toxic pollutant. However, just like nitric oxide NO and carbon monoxide CO, it is 
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considered a gasotransmitter that induces relaxation in the smooth muscles (Mancardi et al 
2009). H2S is produced both enzymatically and non-enzymatically in the GI tract. The 
enzymes, cystathionine-B- lyase (CBS) and cystathionine-y-lyase (CSE), are found in the 
GI tract of mice, rat, and the colon of healthy humans. These enzymes are able to produce 
H2S via the reduction of cysteine. Non-enzymatic production of H2S in the GI tract is 
associated with sulfur reducing bacteria present in the large intestine (Wang 2012).  
The best-known physiological role for NO is as an endothelial-derived relaxing 
factor (EDRF) which shows vasorelaxant actions. H2S, like NO, has been shown to induce 
smooth muscle relaxation in the blood vessels as seen with hypertension development in 
mice with CSE knocked out (Kimura, 2011). Relaxation of these smooth muscles occurs 
mostly via the opening of ATP-dependent K+ channels58. This process of causing 
vasodilation of through the opening of ATP-dependent K+ channels preconditions against 
ischemia/reperfusion injury and myocardial infarction. A multitude of findings support this 
concept: K+-dependent ATP channel blockers attenuated H2S induced vasodilation both in 
vivo and in vitro. The relaxing effect of H2S on colonic motility has also been explained, 
in part, by its direct inhibition of the L-type C++ channels. An endothelium-dependent effect 
is also seen to contribute to these vasodilatory properties. In human endothelial cells, H2S 
caused direct inhibition of the angiotensin-converting enzyme and enhanced the 
vasorelaxation induced by NO (Kimura, 2011) (Singh and Lin 2015). 
Antioxidation. H2S also consists of a thiol group that allows it to reduce disulfide 
bonds and carry out biological effects as an antioxidant. In neurodegenerative diseases, like 
Alzheimer’s, H2S exerts its antioxidant function as a peroxynitrite scavenger. In the brain’s 
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of Alzheimer patients, considerably low levels of H2S are noted with protein nitration by 
peroxynitrite increased. When testing the effects of the ‘H2S’ donor NaSH (sodium 
hydrogen sulfide) in cultured human SH-SY5Y cells, H2S significantly inhibited 
peroxynitrite-mediated tyrosine nitration, peroxynitrite-induced cytotoxicity, intracellular 
protein nitration and protein oxidation (Whiteman et al., 2004).  
Another H2S donor/prodrug, SG1002, was used to investigate its effects on stress 
induced hypertrophic signaling in murine HL1 cardiomyocytes. SG1002 increased levels 
of H2S producing enzyme, CBS, as well as significantly inhibiting H2O2 and ET-1/Phe 
induced oxidative stress (Whiteman et al., 2004).  
Treatments. It is understood that dystrophin loss predisposes all muscle fiber types 
to contraction-induced damage that ultimately leads to muscle degeneration (Lim et al., 
2017). Today, treatment for DMD uses a multidisciplinary approach as multiple organ 
systems are affected, and these treatments are palliative at best- hoping to manage the 
complications with ambulation, respiration, and cardiac health in DMD patients. 
Prolonged, high-dose corticosteroid treatment has been most widely utilized due its 
effectiveness in delaying the disease progression by specifically affecting the aspect of 
muscle wasting presented in DMD (Biggar et al., 2001). Steroidal drugs such as prednisone 
and deflazacort have shown to preserve muscle function, with increasing muscle mass and 
slowing muscular degradation. However, the therapeutic benefits of corticosteroid 
treatment are temporary, with disease progression only being delayed and various adverse 
side effects such as growth retardation, weight gain, hypertension, and cataracts developing 
(Hori et al., 2011) (Merlini et al 2003)  
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Now, as aforementioned, oxidative stress is an important downstream signal in the 
dystrophin process, particularly due to the dysregulation of intracellular Ca++ homeostasis 
caused by contraction-induced damage and mitochondrial damage. The existence of this 
hyper oxidative status in the DMD phenotype not only implicates the role of ROS in the 
pathophysiology of DMD, but also the importance of antioxidant therapeutics for DMD 
treatment. Recently, antioxidants such as resveratrol and melatonin have been used for 
DMD treatment in mdx mice, and they presented a reduction in ROS levels, fibrosis, 
cardiac dysfunction, and an increase in lifespan (Biggar et al 2001) (Hori et al  2011) 
(Chahbouni et al 2010).  
 
1.15: Mouse Models of DMD 
Knowledge of how lack of the gene for the cytoskeleton protein dystrophin leads to 
DMD has led to the development of various mouse models used for DMD research.  
There are both naturally occurring and laboratory-generated animal models that are 
used to study the pathophysiology of DMD and therapeutic efficacy of drugs on the disease. 
Currently, there are around 60 different mouse models for DMD (Mcgreevy et al., 2015).  
The standard model of DMD is the mdx mouse, which carries the mutated 
dystrophin gene that is found in DMD patients. However, despite this deficiency in 
dystrophin, mdx mice lack the severe clinical manifestations that are present in DMD 
patients- the lifespan is only reduced by ~25% in mdx mice compared to the ~75% 
reduction seen in DMD patients. There is also a well-known discrepancy in the muscular 
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wasting that is displayed in DMD patients compared to the mdx mouse (Mcgreevy et al., 
2015) (Fulmer 2011).  
There are, however, mice models available that overcome this discrepancy, 
displaying a more severe phenotype of the DMD disease. Studies have shown that muscle 
cells of DMD patients have reduced proliferative and regenerative potential than muscles 
of healthy subjects’ due to telomerase shortening. In mice, there is minimal telomerase 
shortening with age progression, which is implicated as a cause for the discrepancy seen 
between mdx mice and DMD patients in regard to muscle degradation. Consequently, the 
mdx/mTR -/- mouse model was created, which is a double knockout (KO) mouse that lacks 
not only dystrophin, but also the telomerase RNA component (Terc) that maintains 
chromosome telomere length. Other major DMD mouse models include: utrophin KO 
mouse (mdx/Utrn -/-), α-dystrobravin KO mouse (mdx/Dtna -/-), α-7 integrin KO mouse 
(mdx/α-7 -/-), and Myod1 deficient mice (mdx/Myod1 -/-) (Fulmer 2011) (Mourkioti et al 
2013).  
 
1.16: Rationale 
The clinical effects of DMD in the large intestine of the gastrointestinal tract are 
commonly seen in DMD affected patients and animal models yet information on the 
mechanism and treatment of these complications have not been evaluated. Most of the 
underlying cause of aberrant GI function is correlated with hypocontractility; however, the 
cause of this hypocontractility in DMD patients and the effect that dystrophin deficiency 
has on contractile protein expression in smooth muscle are unknown. H2S is a well-known 
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gasotransmitter that promotes gut motility and regulates the expression of contractile 
proteins by its signaling pathway as an inhibitory transmitter. Nonetheless, its effect on 
colonic motility in DMD is unknown.  
Hypothesis. My aim is to investigate the effect the DMD phenotype has on the 
levels of thin-filament associated proteins and colonic smooth muscle contractility. I 
hypothesize that the lack of dystrophin will lead to a decrease in contractile protein mRNA 
expression and smooth-muscle function. Furthermore, oxidative stress is considered an 
important process in the pathophysiology of DMD, thus, my aim is to also examine whether 
H2S, which is known to have antioxidant function, can restore the effects of dystrophin 
deficiency. I hypothesize that H2S treatment restores the effects of dystrophin deficiency.  
Approach. Contraction and relaxation of colonic segments were measured in their 
longitudinal orientation from 3-month-old control and mdx mice, and 9-month-old control 
and mdx/mTR mice using organ bath systems. The effect of the H2S prodrug, SG1002, was 
tested in mdx/mTR mice. The expression of contractile proteins in mdx and mdx/mTR mice 
along with their age-matched control was measured using qRT-PCR and Western Blotting.  
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Chapter 2: MATERIALS AND METHODS 
 
2.1 : Reagents 
Antibodies for Calponin, Caldesmon, and Smoothelin were obtained from Abcam 
(Cambridge, MA). Antibody for Tropomyosin was obtained from Santa Cruz 
Biotechnologies, Inc. (Dallas, TX); GAPDH was obtained from Cell Signaling Technology 
(Danvers, MA) RNAqueousTM kit, TRIzol Reagent, High-capacity cDNA Reverse 
Transcription Kit, PCR Primers for Calponin (Cnn1 Mm00487032-m1 59 bp), Caldesmon 
(Cald1Mm00513995-m1 102 bp), Tropomyosin (Tpm2 Mm00437172-g1 97 bp), 
Smoothelin (Smtn Mm00449973 m1 66 bp), GAPDH (NM-008084.2 107 bp), β-actin 
(Actb Mm02619580-g1), and 18-S (4332641)were obtained from Thermo Fisher 
(Waltham, MA); Western Blotting materials, 2x Laemmli Sample Buffer,  DCTM Protein 
Assay Reagents, Clarity Max Western ECL Substrate, Clarity Western ECL were obtained 
from Bio-Rad Laboratories (Hercules, CA) T-PER® Tissue Protein Extraction Reagent was 
obtained from Thermo Scientific (Rockford, IL). All other supplies from Sigma, (St.Louis, 
MO); and Fisher Scientific, (Asheville, NC).  
 
2.2 : Animals 
3-month-old female wild-type (WT) and mdx mice (C57BL/6) were purchased from 
Jackson Laboratory (Sacramento, California). The mice were housed in an animal facility 
directed by the Division of Animal Resources at VCU. 9-month-old male WT, mdx/mTR, 
and mdx/mTR treated mice were received from Dr. Salloum’s lab at Sanger Hall, who 
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purchased their mice from the Jackson Laboratory (Sacramento, California). All 
procedures were approved by the Institutional Animal Care and Use Committee (IACUC) 
of the Virginia Commonwealth University. 
 
2.3 : H2S Treatment 
mdx/mTR mice in Dr. Salloum’s lab were treated with the H2S prodrug, SG1002, at 
different time intervals, creating two different treatment cohorts of mice. SG1002, the 
orally active slow-releasing H2S prodrug, was administered as 40 mg/kg of body weight in 
chow/every 3 days in mdx/mTR mice: Early treated mice were given SG1002 from 21 days 
old to 12 months, and late treated mice were given SG1002 from 7 months to 12 months 
old.  
 
2.4 : Collection of Tissue/Preparation of Colonic Tissue 
Mice were euthanized by CO2 inhalation and carefully observed for signs of 
complete cessation. Vertical incisions on the abdomen of the mouse model were 
performed, and the colon was removed and placed in smooth muscle buffer (SMB), 1X 
phosphate-buffered saline (PBS), or Krebs buffer solution, depending on the experimental 
method being performed. Luminal contents of the colonic tubes were appropriately flushed 
with a blunt syringe filled with SMB, PBS, or Krebs buffer. The colonic tubes were cut 
opened along the meso-colon with surgical ring scissors. The mucosa was carefully scraped 
from the smooth muscle layer, containing enteric neurons and smooth muscle cells 
(SMC’s) via round edged forceps.  
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For RNA isolation and lysate preparation, tissues were cut on ice and kept 
‘hydrated’ with PBS. For smooth muscle cell isolation, tissues were placed in SMB [NaCl 
120 mM, KCl 4 mM, KH2PO4 2.6 mM, CaCl2 2.0 mM, MgCl2 0.6 mM, HEPES (N-2-
hydroxyethylpiperazine-N’ 2-ethanesulfonic acid) 25 mM, glucose 14 mM, and Basic 
Eagle Medium (essential amino mixture) 2.1% (pH 7.4)]. For organ bath studies, Segments 
of colon, approximately 1 cm long, were immediately collected/removed and lacerated 
along the long axis of the mesenteric border. The mucosa was abraded carefully. The 
resulting longitudinal segments of colon tissue were pinned in a flat petri dish containing 
warm (37°C), oxygenated Krebs buffer solution [118 mM NaCl, 4.8 mM KCl, 1 mM 
MgSO4, 1.15 mM NaH2PO4, 15 mM NaHCO3, 10.5 mM glucose and 2.5 mM CaCl2 (95% 
O2/5% CO2, pH 7.4, 37°C). 
 
2.5 : Preparation of Dispersed Smooth Muscle Cells  
Smooth muscle cells were isolated from the colon by sequential enzymatic 
digestion, filtration, and centrifugation. Colonic tissue, carefully removed of the mucosa 
and chopped via surgical shears as aforementioned, was incubated at 31°C for 10-15 
minutes in SMB containing 0.1 % collagenase and 0.01% of soybean trypsin inhibitor. The 
partially degraded tissue was washed once with collagenase-free SMB and permitted to 
disperse spontaneously for 20 minutes. Cells were then colleceted/harvested through a 500 
um Nitex every 10 minutes.  
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2.6 : Measurement of Contraction in Muscle Strips 
The isolated smooth muscle strips were tied at the proximal and distal end by silk 
thread using caution as to not restrict the luminal portion. Each colonic segment was 
longitudinally mounted between a glass rod and isometric force transducer and submerged 
in an organ bath. Each organ bath was filled with either 7ml or 3.5 ml of Kreb’s (depending 
on the size of the organ bath) and bubbled continuously with 95% O2 and 5% CO2 at 37°C 
to maintain constant temperature in the bath systems. All the strips were raised to 0.7-0.8 
grams of tension and allowed to equilibrate for 1 hour, with flushing and refilling organ 
baths with Krebs solution every 15 minutes. Contraction was induced via muscarinic 
receptor activation (acetylcholine) at a concentration of 10 µM of acetylcholine (Ach). 
Relaxation was measured in response to 10 µM of sodium-nitroprusside (SNP), a NO donor 
that induces relaxation. The contractile response of the colonic segments to muscarinic 
receptor activation was measured in grams and expressed as mN/100 mg of tissue by 
multiplying grams by 9.8 mN. At the end of each experiment, the strips were blotted dry 
and weighed (tissue wet weight). The mean tissue weight of 3-month-old control mice was 
10.66+1.53 and the mean tissue weight of 3-month-old mdx mice was 10.75+1.38.  
 
2.7 : Measurement of Contraction in Dispersed Smooth Muscle Cells   
Contraction in freshly dispersed colonic muscle cells was determined by scanning 
micrometry. A cell aliquot consisting of 10-4 cells/ml was treated with 500 µl of medium 
containing acetylcholine (ACh, 10 µM) for 30 s or 5 minutes and the reaction was 
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terminated with 1% acrolein at a final concentration of 0.1%. Acrolein, which kills and 
fixes cells without affecting the cell length. The resting cell length was determined in 
control experiments in which muscle cells were incubated with 500 µl of 0.1% bovine 
serum albumin without the ACh. The mean lengths of 50 muscle cells treated with 
acetylcholine was measured by scanning micrometry and compared with the mean lengths 
of untreated cells. The contractile response was expressed as the percent decrease in mean 
cell length from control cell length. 
Relaxation was measured in intact muscle cells contracted with ACh (1 μM). 
Muscle cells were treated for 5 minutes with isoproterenol (10 μM) followed by ACh for 
30 s or 5 min. The reaction was terminated with 1% acrolein. The length of 50 cells treated 
with acetylcholine was measured in sequential microscopic fields by scanning micrometry. 
Relaxation was expressed as percent increase in the length of cells contracted with ACh. 
 
2.8 : Qualitative Real-Time PCR Analysis (qRT-PCR) 
To obtain mRNA from colonic tissue, 1 mL of TRIzol reagent was added to ~40-
100 mg of tissue. The mixture was homogenized via Fisher PowerGen 125 homogenizer. 
200 µL of chloroform was added to separate the solution in an aqueous and organic phase. 
The RNA remained in the aqueous phase. The solution is vortexed and allowed to incubate 
at room temperature for 5 minutes, then centrifuged at 13.3 rpm at 4°C for 15 minutes. The 
superior aqueous phase was transferred to a new autoclaved eppendorf tube and 0.5 ml of 
isopropanol was added to dissolve any salts that may have chelated on the RNA samples. 
The solution is vortexed and centrifuged at 13.3 rpm at 4°C for 20 minutes. The resulting 
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supernatant is then discarded, and 1 ml of ethanol is added, allowing precipitation of RNA 
out of the aqueous solution. The mixture is centrifuged at 13.3 rpm at 4°C for 10 minutes. 
The ethanol was then removed, and the eppendorf tubes are vacuum dried until all liquid 
phase contents have been evaporated. Twenty-five microliter of RNase and DNase free 
ultrapure distilled water is added and the tubes are allowed to incubate at 65°C for 10 
minutes. Concentration was measured using Nanodrop8000.  
RNA from each preparation was reversely transcribed using the High Capacity 
cDNA reverse transcription kits to prepare the 2x RT Master Mix [10x RT Buffer, 25x 
dNTP Mix, 10x RT Random primers, Multiscribe Reverse Transcriptase, Nuclease Free 
H2]. An equal volume of RNA was added to 2xRT Master Mix.  Quantitative RT-PCR was 
then performed on cDNA samples using the specific primers of: Tropomyosin, Caldesmon, 
Calponin, and Smoothelin, based on known sequences in mouse and Taqman gene 
expression master mix. 18-S and β-actin expression were used as controls to normalize 
expression of the target genes. The primers were designed to satisfy the use of 2-∆∆CT 
method, which is the standard method of comparing gene expression between two groups. 
With 18-S/β-actin acting as controls, a quantitative comparison between mdx, mdx/mTR 
and their age-matched control was calculated using the 2-∆∆CT method. Final calculations 
were expressed as a fold difference in the expression of mdx, mdx/mTR, and treated 
mdx/mTR mice cohorts relative to their age-matched control.  
 
2.9 : Western Blot Analysis 
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Colonic tissue, not exceeding 50 mg, were taken from animal models, cleaned and 
removed of the mucosa (as aforementioned), and transferred into new eppendorf tubes with 
appropriate amounts of 1.44mm beads and TPER (lysis buffer) in the presence of protease 
inhibitor. Bead number was calculated as 5 times the tissue weight with TPER volume 
being double the tissue weight.  Tissues were homogenized using a bullet blender. The 
supernatant was collected and centrifuged at 13.3 rpm at 4°C for 10 minutes. Protein 
concentration was then measured using a DC protein assay kit from Bio-Rad. Equal 
amounts of proteins were fractionated by SDS/PAGE and transferred on to Polyvinylidene 
difluoride (PVDF) membrane.  Blots were blocked with 1X TBS with 1% casein blocker 
for 1 hour at room temperature and then incubated overnight at 4 °C with various primary 
antibodies in 1X TBS with 1% casein (Calponin 1:5000, Tropomyosin 1:1000, Caldesmon 
1:10,000, Smoothelin 1:5000). After incubation for 1 h with horseradish-peroxidase-
conjugated corresponding secondary antibody (1:5000) in 1X TBS with 1% casein, 
immunoreactive proteins were visualized using Clarity Max Western ECL Substrate, 
Clarity Western ECL Substrate, or SuperSignal West Pico Chemiluminescent Substrate kit. 
All washing steps were performed with TBS-T. The protein bands were identified by 
enhanced chemiluminescence reagent. 
 
3.0: Statistical Analysis 
 Data and results are presented as means ± Standard Error Mean (SEM). All 
experiments were completed four or more times. Results were analyzed for statistical 
significance using unpaired student T tests. p values < 0.05 were considered significant.  
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Chapter 3: RESULTS 
 
3.1 Effect of DMD on Smooth Muscle Contraction and Relaxation 
 To assess the role of what dystrophin loss has on colonic smooth muscle function, 
we utilized mdx and mdx/mTR mouse models of that lack dystrophin and express the DMD 
phenotype.  Effect of H2S treatment on the smooth muscle contractile function in the 
mdx/mTR mouse model was assessed. Colonic tissue from mdx/mTR mice treated with 
SG1002, an orally active slow-releasing compound that provides stable, non-toxic serum 
and tissue levels of H2S. SG1002 is seen to induce cardioprotection in murine models of 
DMD; however, its therapeutic potential in the GI tract of DMD mice has not been 
evaluated.  Colonic tissue from mdx/mTR mice and mdx/mTR mice treated with SG1002 
were kindly provided by Dr. Salloum.  Smooth muscle function was measured as 
contraction in response to acetylcholine (activator of the main excitatory muscarinic 
receptor pathway), and relaxation in response to sodium nitroprusside, nitric oxide (NO) 
donor (activator of the main inhibitory nitrergic pathway) and isoproterenol (activator of 
inhibitory β-adrenergic pathway).  Contraction and relaxation were measured in intact 
colonic muscle segments and isolated colonic muscle cells.   
 Contraction and relaxation in muscle strips.  For isometric contractions, intact 
colonic segments from mdx mice, mdx/mTR mice, and their age matched control were 
placed longitudinally in an organ bath with Krebs buffer. Acetylcholine (ACh, 10 µM) was 
administered to induce contraction in the colonic tissues. Force of contraction was 
measured in grams. In muscle segments from control mice acetylcholine typically 
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produced 0.7±0.2 g of contraction and the contraction was inhibited (0.3±0.1 g) in muscle 
segments from mdx mice (Figure 3, left panel).  Contraction in grams was normalized to 
tissue and presented as mN/100 mg tissue.  ACh-induced contractions in colonic muscle 
segments from mdx mice was significantly lower compared to their age-matched control 
(15.6+3.9 mN/100 mg tissue in control and 3.8+1.4 mN/100 mg tissue in mdx mice; 
p<0.05, n=4-5) (Figure 3, right panel).  
ACh-induced contraction was also significantly decreased in colonic segments from 
mdx/mTR mice compared to their age-matched control (12.4+2.3 mN/100 mg tissue in 
control and 4.2+1.3 mN/100 mg tissue in mdx/mTR mice; p<0.05, n=4) (Figure 4). 
Although, mdx/mTR mice are shown to exhibit much severe phenotype of DMD, inhibition 
of contraction in colonic muscle strips from mdx mice is observed to be slightly greater 
than the inhibition in colonic segments mdx/mTR mice (73±6% inhibition in mdx mice 
versus 65±6% inhibition in mdx/mTR mice).   
Isometric contractions of colonic segments from mdx/mTR mice treated with 
SG1002 were also evaluated.  Acetylcholine-induced contraction in colonic segments from 
mdx/mTR mice treated with SG1002 was significantly improved compared to colonic 
segments from mdx/mTR mice (9.2+1.4 mN/100 mg in mdx/mTR mice treated with SG1002 
versus 4.2±1.3 in mdx/mTR mice) (Figure 4).   The inhibition of contraction in mdx/mTR 
mice treated with SG1002 was significantly less compared to mdx/mTR mice (23±5% 
inhibition versus 65±6% in mdx/mTR mice. p < 0.01, n=4).  These results suggest that H2S 
reversed the decrease in smooth muscle contraction in mdx/mTR mice and restored closer 
to normal levels.  
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Relaxation in response to SNP in muscle strips was measured as inhibition of ACh-
induced contraction.  Muscle strips were treated with ACh (10 µM) and after attaining a 
stable contraction, SNP (10 µM) was added to measure relaxation. SNP induced complete 
relaxation of ACh-induced contraction in muscle strips from control, mdx and mdx/mTR 
mice.  There was no significant difference in relaxation in response to SNP between mdx 
mice and their age matched control (96±2% in control and 94±3% in mdx mice) and 
mdx/mTR mice, mdx/mTR mice (treated with SG1002) and their age-matched control 
(125±5% in  control mice, 105+10 in mdx/mTR mice and 108±7% in mdx/mTR mice treated 
with SG1002) (Figures 5 and 6). These results suggest that relaxation in response to NO 
donor was not affected in colonic muscle of mdx and mdx/mTR mice.   
 Contraction and relaxation in isolated muscle cells.  Contraction and relaxation in 
response to acetylcholine and SNP in innervated muscle strips could be accredited to the 
release of transmitters from enteric neurons and/or to the effect of interstitial cells of Cajal 
(ICC) that modulate the intrinsic electrical and mechanical activity of smooth muscles. To 
identify the specific involvement of smooth muscle dysfunction to the muscle itself, 
colonic muscle cells devoid of enteric neurons and ICC were isolated from mdx mice and 
their age-matched controls, and contraction in response to ACh was measured and 
expressed as the percent decrease in basal cell length. The kinetic of acetylcholine-induced 
contraction consists of an initial Ca++-dependent phase involving activation of 
Ca++/calmodulin-dependent MLC kinase and increase in MLC20 phosphorylation and a 
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Ca++-independent phase involving inhibition of MLC phosphatase and increase in MLC20 
phosphorylation.  We measured both initial and sustained contraction in response to ACh 
in isolated muscle cells.  
The basal cell lengths of colonic smooth muscle cells were not significantly 
different in control mice and mdx mice (68±4 µm in control mice and 64±6 µm in mdx 
mice).  Treatment of cells with ACh for 0.5 min (initial contraction) caused a significant 
decrease in muscle cell length both in the colon of control and mdx mice.  However, the 
contraction in response to ACh was significantly inhibited in muscle cells from colon of 
mdx mice compared to control mice (43±5% decrease in cell length in control mice and 
25+3% decrease in muscle cell length in mdx mice; p<0.05, n=4-5) (Figure 7).  Treatment 
of cells with ACh for 5 min (sustained contraction) caused a significant decrease in muscle 
cell length both in the colon of control and mdx mice.  However, the contraction in response 
to ACh was significantly inhibited in muscle cells from colon of mdx mice compared to 
control mice (40+4% in control and 27+3 in mdx mice; p<0.05, n=4-5) (Figure 8).   The 
results in isolated muscle cells are consistent with the results in muscle strips and suggest 
that inhibition of contraction in colonic muscle strips is due to a defect in the mechanisms 
that regulate contraction intrinsic to smooth muscle cells.  
In colonic smooth muscle, inhibitory transmitters that activate cAMP/PKA or 
cGMP/PKG pathway cause muscle relaxation. To examine whether the pathways that 
mediate relaxation was affected in mdx mice, relaxation was also measured in isolated 
smooth muscle cells from the colon of control and mdx mice.  To measure relaxation, 
muscle cells were pretreated with SNP (10 µM) or isoproterenol (10 µM) and contraction 
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in response to ACh (1 µM) was measured.  Decrease in ACh-induced contraction in the 
presence of SNP or isoproterenol reflects muscle relaxation and it was expressed as percent 
inhibition of contraction (i.e., relaxation).  Relaxation in response to SNP was not 
significantly different in muscle cells isolated from the colon of control and mdx mice.  
SNP caused 83±12% relaxation in muscle cells from control mice and 92±6% relaxation 
in muscle cells from mdx mice.  (Figure 9).  These results suggest that NO-dependent 
relaxation mediated via cGMP/PKG pathway was not different in colonic muscle cells 
from control versus mdx mice.   Isoproterenol also caused 79±6% relaxation in muscle cells 
from control mice and 77±5% relaxation in muscle cells from mdx mice.  (Figure 10).  
These results suggest that G protein-coupled receptor-dependent relaxation mediated via 
cAMP/PKA pathway was not different in colonic muscle cells from control versus mdx 
mice.  The results in isolated muscle cells are consistent with the results in muscle strips 
and suggests that intrinsic relaxation mechanisms mediated by cAMP/PKA and 
cGMP/PKG pathway are not altered in mdx mice.   
 
3.2 Changes in the Expression of Thin Filament-Associated Proteins 
In smooth muscle contraction is mediated by interaction of actin with myosin.  
However, this interaction is modulated by thin filament associated proteins.   In the present 
study, we also analyzed the changes in expression of the thin filament-associated proteins 
caldesmon, calponin, tropomyosin, and smoothelin by qRT-PCR and western blot in 
smooth muscle of colon isolated from mdx, mdx/mTR, and their age-matched control mice.  
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 Caldesmon. Caldesmon is a thin-filament associated protein that regulates smooth 
muscle contraction via its interaction with actin. Caldesmon has two isoforms, h-caldesmon 
that is smooth muscle specific and l-caldesmon that is a non-muscle isoform (Morgan KG, 
2001). Expression of caldesmon mRNA was measured using primers specific for smooth 
muscle isoform by qRT-PCR in colonic smooth muscle from control and mdx mice and 
expressed as fold change from control levels. Expression of caldesmon mRNA was 
significantly decreased in colonic smooth muscle from mdx mice compared to control 
levels (p <0.05, n=4-5) (Figure 11 Left Panel). Expression of caldesmon protein was 
measured using antibodies that are not specific to smooth muscle isoform.  Western blot 
analysis showed no changes in the expression of caldesmon in colonic smooth muscle 
between control and mdx mice (Figure 11 Right Panel).  
Expression of caldesmon mRNA was also significantly decreased in mdx/mTR mice 
compared to control levels and the decrease in expression was partly reversed by treatment 
of mdx/mTR mice with SG1002 (Figure 12).  The effect of SG1002 on caldesmon mRNA 
expression was significant (p<0.05, n=4).  
Calponin: Calponin is another thin filament-associated protein that exists in three 
isoforms, h1-acidic, h2-neutral, and basic calponin. The h1-acidic isoform is smooth-
muscle specific, whereas the other two are non-muscle isoforms. Expression of calponin 
mRNA was measured using primers specific for smooth muscle isoform by qRT-PCR in 
colonic smooth muscle from control and mdx mice and expressed as fold change from 
control levels. Expression of calponin mRNA was significantly decreased in colonic 
smooth muscle from mdx mice compared to control levels (p <0.05, n=4-5) (Figure 13 Left 
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Panel). Expression of calponin protein was measured using antibodies that are not specific 
to smooth muscle isoform.  Western blot analysis showed no changes in the expression of 
calponin in colonic smooth muscle between control and mdx mice (Figure 13 Right Panel).  
Expression of calponin mRNA was also significantly decreased in mdx/mTR mice 
compared to control levels and the decrease in expression was completely reversed by 
treatment of mdx/mTR mice with SG1002 (Figure 14).  The effect of SG1002 on calponin 
mRNA expression was significant (p<0.05, n=4).  
Tropomyosin: Tropomyosin, like calponin and caldesmon, is a thin filament-
associated protein that regulates acto-myosin interaction. Two isoforms of tropomyosin 
exist, α and β tropomyosin. Expression of tropomyosin mRNA was measured using 
primers that are not isoform-specific by qRT-PCR in colonic smooth muscle from control 
and mdx mice and expressed as fold change from control levels. Expression of tropomyosin 
mRNA was significantly decreased in colonic smooth muscle from mdx mice compared to 
control levels (p <0.05, n=4-5) (Figure 15 Left Panel). Expression of the tropomyosin 
protein was measured using antibodies that are not isoform-specific.  Western blot analysis 
showed no changes in the expression of tropomyosin in colonic smooth muscle between 
control and mdx mice (Figure 15 Right Panel).  
Smoothelin: There are two isoforms of smoothelin, smoothelin-A that is specific to 
the visceral smooth muscle and smoothelin-B that is specific to vascular smooth muscle. 
Expression of smoothelin-A mRNA was measured using primers that are specific for 
visceral smooth muscle by qRT-PCR in colonic smooth muscle from control and mdx mice 
and expressed as fold change from control levels. Expression of smoothelin-A mRNA was 
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significantly decreased in colonic smooth muscle from mdx mice compared to control 
levels (p <0.05, n=4-5) (Figure 16 Left Panel). Expression of smoothelin protein was 
measured using antibodies that are not isoform-specific.  Western blot analysis showed no 
changes in the expression of smoothelin in colonic smooth muscle between control and 
mdx mice (Figure 16 Right Panel). 
 
 
 
 
 
 
Figure 3.  Colonic muscle strips were isolated from 3-month old control and mdx mice. 
Contraction in response to acetylcholine (10 µM) was measured in organ bath experiments. 
Contraction was recorded as increase in grams and calculated as mN/100g mg tissue.  Left panel: 
Bar graphs of calculated values (n=4-5). Right panel: Representative tracing of acetylcholine-
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induced contraction in colonic muscle strips from control and mdx mice.  Contraction was 
significantly decreased in mdx mice.  ** p <0.05, n=4-5 
  
 51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Colonic muscle strips were isolated from 9-month old control and mdx/mTR mice and 
mdx/mTR mice treated with SG1002, an orally active H2S donor. Contraction in response to 
acetylcholine (10 µM) was measured in organ bath experiments. Contraction was recorded as 
increase in grams and calculated as mN/100g mg tissue.  Contraction was significantly decreased 
in mdx/mTR ( ** p <0.05, n=4).  Treatment with SG1002 partly and significantly reversed the 
inhibition in contraction (## p < 0.05, n=4).  
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Figure 5.  Colonic muscle strips were isolated from 3-month old control and mdx mice. Relaxation 
in response to nitric oxide donor, sodium nitroprusside (SNP, 10 µM) was measured as inhibition 
of acetylcholine (10 µM)-induced contraction and calculated as percent inhibition of contraction.  
SNP completely inhibited contraction in colonic muscle strips from both control and mdx mice 
(n=4-5) 
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Figure 6.  Colonic muscle strips were isolated from 9-month old control and mdx/mTR mice and 
mdx/mTR mice treated with SG1002, an orally active H2S donor. Relaxation in response to nitric 
oxide donor, sodium nitroprusside (SNP, 10 µM) was measured as inhibition of acetylcholine (10 
µM)-induced contraction and calculated as percent inhibition of contraction.  SNP completely 
inhibited contraction in colonic muscle strips from control and mdx/mTR mice and in mdx/mTR 
mice treated with SG1002 (n=4) 
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Figure 7.  Smooth muscle cells were isolated from the colon of 3-month old control and mdx mice. 
Cells were treated with acetylcholine (1 µM) for 0.5 min and contraction was measured as 
decrease in cell length from the basal length (control: 68±4 µm and mdx: 64±6 µM) and expressed 
as percent decrease in cell length.     Initial contraction was significantly decreased in mdx mice.  
** p <0.05, n=4-5 
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Figure 8.  Smooth muscle cells were isolated from the colon of 3-month old control and mdx mice. 
Cells were treated with acetylcholine (1 µM) for 0.5 min and contraction was measured as 
decrease in cell length from the basal length (control: 68±4 µm and mdx: 64±6 µM) and expressed 
as percent decrease in cell length.     Sustained contraction was significantly decreased in mdx 
mice.  ** p <0.05, n=4-5 
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Figure 9.  Smooth muscle cells were isolated from the colon of 3-month old control and mdx mice. 
Relaxation in response to nitric oxide donor, sodium nitroprusside (SNP, 10 µM) was measured as 
inhibition of acetylcholine (1 µM)-induced contraction and calculated as percent inhibition of 
contraction.  SNP-induced relaxation was not different in colonic smooth muscle cells from both 
control versus mdx mice (n=4-5) 
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Figure 10.  Smooth muscle cells were isolated from the colon of 3-month old control and mdx 
mice. Relaxation in response to β-adrenergic agonist isoproterenol (10 µM) was measured as 
inhibition of acetylcholine (1 µM)-induced contraction and calculated as percent inhibition of 
contraction.  Isoproterenol-induced relaxation was not different in colonic smooth muscle cells 
from both control versus mdx mice (n=4-5) 
 
 
 
 
 
 
  
 
0
2 0
4 0
6 0
8 0
1 0 0
Control mdx
R
el
a
x
a
ti
o
n
 (
%
)
 58 
 
 
 
 
Figure 11.  Expression of caldesmon in colonic smooth muscle of control and mdx mice Left Panel:  
RNA was isolated from colonic smooth muscle of 3-month old control and mdx mice. mRNA 
expression of caldesmon was measured using specific primers by quantitative RT-PCR and 
expressed as fold change over control.  mRNA expression of caldesmon was significantly decreased 
in colonic smooth muscle from mdx mice compared to control (** p<0.05, n=4-5).  Right panel:  
Lysates were prepared from colonic smooth muscle of control and mdx mice and expression of 
caldesmon was measured by western blot using specific antibody.  Representative western blot 
image of 4 separate experiments was shown in the figure.  Densitometry analysis of all the images 
showed no difference in the expression of caldesmon in colonic smooth muscle between control 
and mdx mice. 
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Figure 12.  Effect of H2S on caldesmon expression in colonic smooth muscle of mdx/mTR mice.  
Left Panel:  RNA was isolated from colonic smooth muscle of 9-month old control and mdx/mTR 
mice and mdx/mTR mice treated with SG1002, an orally active H2S donor mRNA expression of 
caldesmon was measured using specific primers by quantitative RT-PCR and expressed as fold 
change over control.  mRNA expression of caldesmon was significantly decreased in colonic 
smooth muscle from mdx/mTR mice compared to control (** p<0.05, n=4). Treatment with SG1002 
significantly reversed the inhibition in caldesmon mRNA expression (## p<0.05, n=4).  
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Figure 13.  Expression of calponin colonic smooth muscle of control and mdx mice Left Panel:  
RNA was isolated from colonic smooth muscle of 3-month old control and mdx mice. mRNA 
expression of calponin was measured using specific primers by quantitative RT-PCR and expressed 
as fold change over control.  mRNA expression of calponin was significantly decreased in colonic 
smooth muscle from mdx mice compared to control (** p<0.05, n=4-5).  Right panel:  Lysates 
were prepared from colonic smooth muscle of control and mdx mice and expression of calponin 
was measured by western blot using specific antibody.  Representative western blot image of 4 
separate experiments was shown in the figure.  Densitometry analysis of all the images showed no 
difference in the expression of calponin colonic smooth muscle between control and mdx mice. 
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Figure 14.  Effect of H2S on calponin expression in colonic smooth muscle of mdx/mTR mice.  Left 
Panel:  RNA was isolated from colonic smooth muscle of 9-month old control and mdx/mTR mice 
and mdx/mTR mice treated with SG1002, an orally active H2S donor mRNA expression of calponin 
was measured using specific primers by quantitative RT-PCR and expressed as fold change over 
control.  mRNA expression of calponin was significantly decreased in colonic smooth muscle from 
mdx/mTR mice compared to control (** p<0.05, n=4). Treatment with SG1002 significantly 
reversed the inhibition in calponin mRNA expression (## p<0.05, n=4).  
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Figure 15.  Expression of tropomyosin in colonic smooth muscle of control and mdx mice Left 
Panel:  RNA was isolated from colonic smooth muscle of 3-month old control and mdx mice. mRNA 
expression of tropomyosin was measured using specific primers by quantitative RT-PCR and 
expressed as fold change over control.  mRNA expression of tropomyosin was significantly 
decreased in colonic smooth muscle from mdx mice compared to control (** p<0.05, n=4-5).  Right 
panel:  Lysates were prepared from colonic smooth muscle of control and mdx mice and expression 
of tropomyosin was measured by western blot using specific antibody.  Representative western blot 
image of 4 separate experiments was shown in the figure.  Densitometry analysis of all the images 
showed no difference in the expression of tropomyosin in colonic smooth muscle between control 
and mdx mice. 
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Figure 16.  Expression of smoothelin in colonic smooth muscle of control and mdx mice Left Panel:  
RNA was isolated from colonic smooth muscle of 3-month old control and mdx mice. mRNA 
expression of smoothelin-A was measured using specific primers by quantitative RT-PCR and 
expressed as fold change over control.  mRNA expression of smoothelin-A was significantly 
decreased in colonic smooth muscle from mdx mice compared to control (** p<0.05, n=4-5).  Right 
panel:  Lysates were prepared from colonic smooth muscle of control and mdx mice and expression 
of smoothelin was measured by western blot using specific antibody.  Representative western blot 
image of 4 separate experiments was shown in the figure.  Densitometry analysis of all the images 
showed no difference in the expression of smoothelin in colonic smooth muscle between control 
and mdx mice. 
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Chapter 4: DISCUSSION 
 
Duchenne Muscular Dystrophy is the most common form of inherited muscular 
dystrophies that affects 1 in 3300 male births (Yucel et al., 2018). This genetic disorder is 
caused by a mutation in the gene located at Xp21 which encodes for the cytoskeleton 
protein dystrophin (Yucel et al., 2018).  Dystrophin is present in all types of muscles and 
immunocytochemical studies have localized that dystrophin to the cytoplasmic surface of 
the plasma membrane associating tightly with a complex membrane glycoproteins.  
Because of its association with important structural proteins and sequence similarity with 
other structural proteins such as α-actinin, dystrophin is suggested to have an important 
structural role and provide resilience to the plasma membrane during contraction and 
relaxation.  Dystrophin a large 427 kD protein.  The dystrophin gene is transcribed into 
multiple RNA isoforms that show tissue specificity.  Byers et al have shown that in SDS-
PAGE, dystrophin characteristically appears as a doublet in skeletal and cardiac muscle 
suggesting different isoforms (Byers 1991).  In contrast, dystrophin appears as a single 
band in intestinal smooth muscle.  The levels of dystrophin in smooth muscle are lower 
compared to skeletal muscle (Byers 1991). Electron microscopy and immunofluorescence 
studies showed that dystrophin is specifically localized in caveolae this localization is 
distinct from the adherent junctions containing β1 integrin, fibronectin and vinculin (Byers 
1991) (North et al., 1993). Caveolae are microdomains of the plasma membrane that have 
been implicated in Ca++ homeostasis and signal transduction.   The ability of caveolae to 
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sequester signaling components are due to the scaffolding properties of main caveolar 
protein, cavelin-1.  Disruption of dystrophin-glycoprotein complex leads to increased 
permeability to Ca++ suggesting an important function of dystrophin in the regulation Ca++ 
homeostasis.    
In smooth muscle, Ca++ and G protein-coupled receptor signaling are not only 
important for contraction, but also determine the cell phenotype.  Caveolin-1 and the 
signaling molecules activated during contraction and relaxation of smooth muscle play an 
important in the regulation of expression of contractile protein and maintenance of 
contractile phenotype.  Loss of caveolin-1 is associated with the decreased smooth muscle 
contraction and relaxation and change to proliferative phenotype (Halayko et al., 2005). 
The importance of caveolin-1 in signal transduction and its association with dystrophin 
highlights the significance of dystrophin in regulation of smooth muscle function.   
Smooth muscle contains contractile apparatus consisting thin filaments as polymers 
of actin monomers and thick filaments as aggregates of myosin filaments.  In addition, 
thin-filaments are associated with proteins such as calponin, caldesmon, tropomyosin and 
smoothelin.  These proteins are shown to play a role in the regulation of acto-myosin 
interaction and contraction albeit the exact mechanism of regulation is not clear.  For 
example, both calponin and caldesmon inhibit acto-myosin interaction and contraction, 
whereas smoothelin promotes contraction.  Interaction of myosin and actin initiates cross-
bridge cycling and this interaction is greatly facilitated by phosphorylation of 20 kDa 
myosin light chain (MLC20).   The levels of MLC20 phosphorylation of are regulated by 
MLC kinase and MLC phosphatase.  Contractile agonists such as acetylcholine cause an 
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increase cytosolic Ca++ to stimulate Ca++/calmodulin-dependent MLC kinase and a 
decrease in MLC phosphatase; both lead to increase in MLC20 phosphorylation.   
 Initially, DMD was considered predominantly a skeletal muscle disorder, clinically 
associated with symptoms such as progressive muscular wasting, waddling gait, 
pseudohypertrophy of the calves, and this overall loss of ambulation. Cardiac 
complications recently became more prominent, as cardiomyopathy and heart failure 
related mortality has increased.  However, with advancing age, DMD patients also suffer 
from many gastrointestinal complications as well, such as bloating, gastroesophageal 
reflux, and highly prevalent, life threatening, constipation. These GI complications have 
not yet been systematically evaluated, and there is little scientific information on the 
pathophysiology and treatment of these conditions in DMD patients (Lo Cascio et al., 
2016) (Petrof et al., 2002) (Shirokova and Niggli 2013). In DMD patients colonic 
dysmotility has been attributed to changes in the peristaltic wave patterns characteristic of 
the large intestine. 
Colonic motility is regulated by enteric neurons, ICC and smooth muscle cells.  In 
addition to the smooth muscle, dystrophin is expressed in enteric neurons and ICC 
(Vannuchhi et al., 2002). Abnormalities in nitrergic neurotransmission have been 
suggested to play a role in altered colonic muscle contraction in innervated colonic muscle 
strips from mdx mice (Mule et al., 2010).To our knowledge, there are no studies on the role 
of dystrophin in the regulation of colonic smooth muscle function.  In the present study we 
tested the hypothesis that dystrophin is essential for normal contraction and absence of 
dystrophin leads to changes in the expression of contractile proteins and decreased 
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contraction.   The present study was undertaken to examine the role of dystrophin using 
isolated smooth muscle cells as well as muscle strips from colon of control and two DMD 
mouse models, mdx and mdx/mTR.  Contraction in response to acetylcholine in muscle 
strips and isolated muscle cells from colon of both mdx and mdx/mTR mice was decreased 
compared to age-matched controls.  Expression of calponin, caldesmon, tropomyosin and 
smoothelin mRNA was also decreased in colonic muscle from both mdx and mdx/mTR 
mice compared to age-matched controls.   These results suggest that changes in smooth 
muscle function contributes, in addition to the altered neurotransmission, to altered gut 
motility in DMD.  This is supported by our functional studies in isolated smooth muscle 
cells devoid of enteric neurons and ICC.  However, given the expression of dystrophin in 
enteric neurons and ICC, we cannot exclude the participation of enteric neurons and ICC 
in the altered gut motility in DMD.   
Another major finding of this study is that treatment of mdx/mTR mice with H2S donor 
restores the mRNA of contractile proteins expression and contractile function similar or 
close to control.  A novel H2S drug, SG1002, has been recently introduced to attenuate 
myocardial cellular damage by increasing antioxidant products. Furthermore, in heart 
failure patients SG1002 was seen to increase circulatory bioavailability of NO and H2S 
(Allen et al., 2010) (Chahbouni et al., 2010).  It is unlikely the effect of H2S is due to rapid 
effect on signaling pathways.  The long-term treatment with H2S points to its role as anti-
oxidant and regulation of transcription factors such as Nrf2 that are involved in the anti-
oxidation and anti-inflammation (Xie et al., 2016).  Among the multiple pathogenic 
mechanisms proposed in DMD, oxidative stress and inflammation have been implicated in 
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the pathophysiology of disease.  In support to this notion, recent studies by Boursereau et 
al (2018) have shown that NLRP3 inflammasome is involved in the pathogenesis of DMD 
and downregulation of NLRP3 inflammasome decreases DMD phenotype (Boursereau et 
al., 2018).  Increase in the activities of NFAT, AP-1 and NF-κB that play a role in 
inflammation are observed in dystrophic muscle (Evans et al., 2009).  Another study 
showed that treatment of mdx mice with the anti-oxidant N-acetyl cysteine decreased 
oxidative stress and protected the muscle fiber from stretch-induced damage (Hori et al., 
2011). Anti-oxidants such as melatonin and resveratrol have been used to ameliorate the 
muscular pathology by scavenging ROS in animal model of DMD (Biggar et al., 2001) 
(Merlini et al., 2003) (Wamhoff et al., 2006). More importantly, currently available 
treatment options for DMD are glucocorticoids and the most the significant effect of 
glucocorticoids is to inhibit expression of inflammatory genes.   
In conclusion, our results demonstrate that in mdx and mdx/mTR mice mRNA 
expression of thin filament associated proteins are decreased and this is associated with 
decrease in smooth muscle contraction.  Our results also demonstrate that treatment of 
mdx/mTR mice with H2S donor restores expression of proteins and contraction in colonic 
smooth muscle.  Our study suggests a therapeutic potential of SG1002 on the DMD 
phenotype.  An important unanswered question remains: what is the effect of absence of 
dystrophin on the intrinsic signaling pathways activated by contractile agonists in smooth 
muscle cells? The lack of dystrophin is known to alter the Ca++ homeostasis and hence it 
is hypothesized that Ca++ regulated activity of MLC kinase and MLC20 phosphorylation 
levels are also altered in mdx and mdx/mTR mice leading to decreased muscle contraction. 
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Finally, though it is clear dystrophin is an important plasma membrane protein that 
provides mechanical stability and its association caveolar proteins caveolin-1 might be 
important for contractile phenotype, future studies are required to elucidate the role of 
dystrophin in the signaling process that regulate smooth muscle contraction. 
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